trader_ron
2年前
$NLBS - Nutralife Biosciences, Inc. operates a multifaceted life sciences company. Since 2013, NutraLife's manufacturing facility has been registered with the FDA and operated in accordance with the GMP standard. The Company manufactures and distributes private label and branded nutraceutical and wellness products. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., the Company provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing. In February of 2019, the Company's subsidiary, NutraDerma Technologies, Inc. acquired its first product, a patented all natural dermal patch designed to ward off insects including mosquitoes.
https://www.otcmarkets.com/stock/NLBS/overview
NF2010
2年前
NutraLife Biosciences Launches a Clinically Tested Focus Stimulant Under a Master Distribution Agreement
October 27, 2022 – COCONUT CREEK, FL – NutraLife Biosciences, Inc. (OTC: NLBS), a manufacturer and distributor of private label and branded nutraceutical and skincare products, today announced it has executed a master distribution agreement with Whole Foods Full Spectrum Processing. (“WFFSP”) for the co-marketing and distribution of Addy, a focus stimulant product designed to enhance sustained attention and support better mental clarity.
Developed by WFFSP, Addy is an all-natural, non-addictive dietary supplement shown in a clinical study to improve two of the so-called “executive functions” of the brain: working memory and sustained attention, both of which are considered important to learning, studying, and test performance in academic settings.
According to medical researchers, the prevalence of ADHD and ADD is on the rise in both adults and children here in the U.S. and around the world. With an estimated 9.4% of children and 2.8% of adults coping with hyperactivity disorders, the global ADHD therapeutics market has an estimated value of $29.56 billion this year and is projected to reach $45.68 billion by 2027.
“We are delighted to have this opportunity to distribute this drug-free, non-GMO, and vegetarian supplement available to everyone interested in enhancing their ability to stay on task with greater focus and concentration, but without jitters or other unwanted side effects,” stated Edgar Ward, President, and CEO of NutraLife.
Based in Coconut Creek, Florida, and publicly traded as over-the-counter security for 8-years, NutraLife Biosciences is a developer, manufacturer, and distributor of more than 50 products and formulations designed to support and cater to a multitude of health and wellness applications to help support healthful body function and improve the quality of life.
Formulated by board-certified addiction specialist Dr. Samuel Amen, Addy’s active ingredient is whole green coffee beans which are sustainably sourced and manufactured in an FDA-certified facility. Due to the unique delivery mechanism native to powdered green coffee beans, in a clinical study conducted by the Cleveland Clinic, Addy appeared to support the ability of subjects to stay on task, focus, and more effectively maintain concentration.
“The availability of a natural substance that assists executive function is a highly useful accommodation that can assist in a wide variety of daily tasks, business activities, and academic pursuits,” commented Dr. Samuel Amen, PhD.
The Cleveland Clinic study investigated the effects of WGCP™ on the ability of neurotypical individuals without diagnosed ADHD to exercise executive functions associated with: sustained attention, spatial working memory, response inhibition, and impulsivity, all of which are thought to enhance remote cognitive activity similar to academic study.
Unlike extracted stimulants that can trigger a wide range of adverse side effects, Addy has been clinically shown to increase focus and concentration for 5 to 6 hours in test subjects with no reported side effects.*
To measure the effects of WGCP™ on core executive functions used in standard academic study, the Cleveland Clinic also used the ADHD core battery of the Cambridge neuropsychological test automated battery (CANTAB) and employed a withdrawal protocol to examine the differential effects of WGCP and placebo in neurotypical college-age adults ages 18 to 25 years.
WGCP (“Addy”) is not an ADD/ADHD medication or cure. It is a clinically tested focus & study aid product.
NutraLife Biosciences is making the Addy product available online at www.buyaddy.com/ and will begin distributing the products through various retail online and outlets nationwide.
ABOUT NUTRALIFE BIOSCIENCES, INC.
NutraLife BioSciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than twelve years, NutraLife has manufactured and distributed both private-label and branded nutraceutical and skincare wellness products.
For more information, visit our website at www.nutralifebiosciences.com.
NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com
Forward-Looking Statements
This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on April 11, 2022. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.
NF2010
2年前
NutraLife Biosciences Launches a Clinically Tested Focus Stimulant Under a Master Distribution Agreement
October 27, 2022 – COCONUT CREEK, FL – NutraLife Biosciences, Inc. (OTC: NLBS), a manufacturer and distributor of private label and branded nutraceutical and skincare products, today announced it has executed a master distribution agreement with Whole Foods Full Spectrum Processing. (“WFFSP”) for the co-marketing and distribution of Addy, a focus stimulant product designed to enhance sustained attention and support better mental clarity.
Developed by WFFSP, Addy is an all-natural, non-addictive dietary supplement shown in a clinical study to improve two of the so-called “executive functions” of the brain: working memory and sustained attention, both of which are considered important to learning, studying, and test performance in academic settings.
According to medical researchers, the prevalence of ADHD and ADD is on the rise in both adults and children here in the U.S. and around the world. With an estimated 9.4% of children and 2.8% of adults coping with hyperactivity disorders, the global ADHD therapeutics market has an estimated value of $29.56 billion this year and is projected to reach $45.68 billion by 2027.
“We are delighted to have this opportunity to distribute this drug-free, non-GMO, and vegetarian supplement available to everyone interested in enhancing their ability to stay on task with greater focus and concentration, but without jitters or other unwanted side effects,” stated Edgar Ward, President, and CEO of NutraLife.
Based in Coconut Creek, Florida, and publicly traded as over-the-counter security for 8-years, NutraLife Biosciences is a developer, manufacturer, and distributor of more than 50 products and formulations designed to support and cater to a multitude of health and wellness applications to help support healthful body function and improve the quality of life.
Formulated by board-certified addiction specialist Dr. Samuel Amen, Addy’s active ingredient is whole green coffee beans which are sustainably sourced and manufactured in an FDA-certified facility. Due to the unique delivery mechanism native to powdered green coffee beans, in a clinical study conducted by the Cleveland Clinic, Addy appeared to support the ability of subjects to stay on task, focus, and more effectively maintain concentration.
“The availability of a natural substance that assists executive function is a highly useful accommodation that can assist in a wide variety of daily tasks, business activities, and academic pursuits,” commented Dr. Samuel Amen, PhD.
The Cleveland Clinic study investigated the effects of WGCP™ on the ability of neurotypical individuals without diagnosed ADHD to exercise executive functions associated with: sustained attention, spatial working memory, response inhibition, and impulsivity, all of which are thought to enhance remote cognitive activity similar to academic study.
Unlike extracted stimulants that can trigger a wide range of adverse side effects, Addy has been clinically shown to increase focus and concentration for 5 to 6 hours in test subjects with no reported side effects.*
To measure the effects of WGCP™ on core executive functions used in standard academic study, the Cleveland Clinic also used the ADHD core battery of the Cambridge neuropsychological test automated battery (CANTAB) and employed a withdrawal protocol to examine the differential effects of WGCP and placebo in neurotypical college-age adults ages 18 to 25 years.
WGCP (“Addy”) is not an ADD/ADHD medication or cure. It is a clinically tested focus & study aid product.
NutraLife Biosciences is making the Addy product available online at www.buyaddy.com/ and will begin distributing the products through various retail online and outlets nationwide.
ABOUT NUTRALIFE BIOSCIENCES, INC.
NutraLife BioSciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than twelve years, NutraLife has manufactured and distributed both private-label and branded nutraceutical and skincare wellness products.
For more information, visit our website at www.nutralifebiosciences.com.
NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com
Forward-Looking Statements
This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on April 11, 2022. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.
AngelDay
4年前
$NLBS has a deal to distribute hand sanitizer to help combat Covid-19. Press Release Yesterday:
October 27, 2020 - NutraLife BioSciences, Inc. ( “NutraLife”) ( OTC: NLBS ) has secured distribution of NutraLife’s “Eddie’s Clean Hands” brand of multi-use sanitizer sprays with a national distributor, W.W. Grainger Inc.
Amid the COVID-19 global pandemic, NutraLife has increased its production and was assigned its labeler code from the Food and Drug Administration (FDA) to operate as an over the counter (OTC) manufacturer. NutraLife has taken all the necessary steps to ramp up production while adhering to FDA guidelines for the formulating, packaging, labeling, and distribution of its sanitizer products.
In May 2020, NutraLife secured a supplier agreement with Grainger, was then onboarded, and began dropshipping its sanitizer products that include a 10-pack of Eddie’s Clean Hands 2 oz. sanitizer spray along with a larger 8 oz. sanitizer spray directly to Grainger and its customers.
Grainger is a broad line, business-to-business distributor of maintenance, repair, and operating (MRO) products and services with operations primarily in North America, Japan, and Europe. Grainger serves a large number of customers in diverse industries and offers more than 1.5 million products, a consultative sales approach, and product expertise, a premium digital experience, and the ability to quickly get complete orders to over 3.5 million customers to help keep their operations running and their people safe.
Over the past few months, NutraLife has achieved a 100% performance scorecard report with Grainger based on supplier compliance, prompting Grainger to transition from a dropship supplier of Eddie’s Clean Hands sanitizer sprays to stocking the items within the Grainger distribution system. The transition has provided NutraLife with increased order flow, exposure, and brand awareness for its sanitizer products, along with a platform to introduce its other exclusive and non-exclusive products, as the relationship between the two companies continues to mature.
ADVERTISEMENT
“We are pleased and grateful to have the opportunity to work with Grainger, and we take pride in the quality and service of the products we produce. We believe having the strength of a national distributor, along with the exposure that it brings, will help to build a solid foundation and brand asset value for NutraLife, and we look forward to a fruitful and long-lasting relationship,” said Edgar Ward, President/CEO of NutraLife BioSciences, Inc.
About the Company
NutraLife BioSciences, Inc. operates a multifaceted life sciences company. For more than seven years, NutraLife has manufactured and distributed private label and branded nutraceutical and skincare wellness products.
Forward-Looking Statements
This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on April 2, 2019, as amended. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.
Contact:
NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com
Golden Cross
5年前
September 13, 2019 - NutraLife BioSciences Delivers 30,000 NutraDerma Bug Patch Mosquito Relief Patches to the Bahamas After Hurricane Dorian
GlobeNewswire•September 13, 2019
Coconut Creek, Florida, Sept. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- A NutraLife BioSciences representative, along with several other volunteers from South Florida, delivered 30,000 mosquito repellent patches and other relief supplies from South Florida to the Bahamas on September 7 to aid in the recovery from Hurricane Dorian. In addition to 30,000 NutraDerma mosquito relief patches donated by NutraLife BioSciences, the volunteers delivered items including medicine, medical supplies, diapers, food, water, hygiene kits, flashlights, tents, and propane cooking devices. The supplies arrived at 10:00 am and were immediately distributed to residents of Freeport, Bahamas.
Hurricane Dorian caused large scale destruction in the northwestern Bahamas, with Grand Bahama and the Abaco Islands being the most significantly affected. The death toll remains unknown and thousands are missing. At least 50,000 Bahamians are homeless as a result of the storm.
Among the many health risks posed by Hurricane Dorian is mosquito infestation. Hurricane Dorian resulted in widespread flooding and provided a breeding environment for mosquitoes carrying possibly dangerous and life-threatening diseases.
Edgar Ward, the Chief Executive Officer of NutraLife BioSciences, stated, “We hope that the 30,000 mosquito patches help residents avoid mosquito bites. Our patches are all-natural, with no side effects or harmful ingredients. As a South Florida company, our hearts go out to our neighbors in the Bahamas. We hope our efforts will provide much-needed relief and help our neighbors, colleagues, and all those impacted by Hurricane Dorian begin the long process of recovery as they work to put their lives and communities back together. We will continue to monitor relief efforts in the Bahamas and provide assistance to our neighbors.”
Stock Symbol: OTCQB: NLBS | Coconut Creek, FL. 33073 | 888.509.8901
This communication contains statements of a forward-looking nature about NutraLife BioSciences, Inc., and its wholly owned subsidiary, NutraDerma Technologies, Inc. (collectively the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that Company’s current expectations and projections concerning its ability to commercialize the patented insect dermal patch are accurate. All forward-looking statements in this packet of information are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.
About the Company:
Since the Company was founded in 2010, it has evolved into a branded and private label developer, manufacturer, and distributor of a wide range of nutraceutical, wellness, and CBD products. The Company started with three nutraceutical spray products in 2010. Since then, the Company has evolved into an FDA registered manufacturer of a wide range of life science products that include seventeen (17) different core formulations with over 50 different variations. The Company’s products include:
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Renee
2月前
ChillyWilly1
2年前
Mygolfballs
4年前
Investorr
4年前
Flip
5年前
jjr04001
6年前
